沙门菌脂多糖的结构修饰及其效应的研究进展

doi:10.11843/j.issn.0366-6964.2023.04.005

摘要/Abstract

摘要： 沙门菌（Salmonella）是一种人畜共患病病原菌，对人类和动物的健康具有重大影响，同时给畜牧业造成了重大经济损失，因此其致病机制的深入研究是目前亟待解决的问题。脂多糖（lipopolysaccharide，LPS）位于沙门菌外膜，是一种重要的毒力因子，其结构的修饰会影响沙门菌免疫逃逸能力、抗性和毒力等多种特性。利用这一现象，人为修饰脂多糖后得到的突变体菌株可应用于沙门菌病的防控。此外，经修饰后的低毒性脂多糖因其具有免疫刺激性，因此可应用于疫苗佐剂。基于以上内容，本文将对沙门菌脂多糖的结构修饰及其效应、生物合成与转运、以及脂多糖的应用等方面进行综述，对于此研究进展的掌握有利于沙门菌致病机制的深入研究及沙门菌病的预防与控制。

关键词: 沙门菌, 脂多糖, 结构修饰及效应, 生物合成及转运, 应用

Abstract: Salmonella is a zoonotic pathogen. It has a significant impact on human and animal health, and has caused significant economic losses to animal husbandry. Therefore, it is urgent to explore its pathogenic mechanism. Lipopolysaccharide, located in the outer membrane of Salmonella, is an important virulence factor. The modification of its structure can affect the immune escape ability, resistance and virulence of Salmonella. Based on this phenomenon, the mutant strains obtained by artificially modifying LPS can be used in the prevention and control of salmonellosis. In addition, low-toxicity derivative of LPS can be used to be vaccine adjuvants due to its useful immunostimulatory properties. Based on the above, the structural modification and its effects, biosynthesis and transport, and the application of Salmonella lipopolysaccharides are reviewed in this paper. Grasping the progress of this research is conducive to the in-depth study of the pathogenic mechanism of Salmonella,as well as the prevention and control of disease.

Key words: Salmonella, lipopolysaccharide, structural modification and effects, biosynthesis and transport, application

中图分类号:

S852.61

田艳红, 于江旭, 焦宇洲, 高东阳, 蔡旭旺. 沙门菌脂多糖的结构修饰及其效应的研究进展[J]. 畜牧兽医学报, 2023, 54(4): 1392-1402.

TIAN Yanhong, YU Jiangxu, JIAO Yuzhou, GAO Dongyang, CAI Xuwang. Research Progress on Structural Modification and Its Effects of Salmonella Lipopolysaccharides[J]. Acta Veterinaria et Zootechnica Sinica, 2023, 54(4): 1392-1402.

参考文献 55

[1]	LEYMAN B, BOYEN F, VAN PARYS A, et al. Salmonella Typhimurium LPS mutations for use in vaccines allowing differentiation of infected and vaccinated pigs[J]. Vaccine, 2011, 29(20):3679-3685.
[2]	HOELZER K, MORENO SWITT A I, WIEDMANN M. Animal contact as a source of human non-typhoidal salmonellosis[J]. Vet Res, 2011, 42(1):34.
[3]	BESSER J M. Salmonella epidemiology:a whirlwind of change[J]. Food Microbiol, 2018, 71:55-59.
[4]	GUO R X, LI Z Y, JIAO Y, et al. O-polysaccharide is important for Salmonella Pullorum survival in egg albumen, and virulence and colonization in chicken embryos[J]. Avian Pathol, 2017, 46(5):535-540.
[5]	RAETZ C R H, WHITFIELD C. Lipopolysaccharide endotoxins[J]. Annu Rev Biochem, 2002, 71:635-700.
[6]	AKIRA S, TAKEDA K. Toll-like receptor signalling[J]. Nat Rev Immunol, 2004, 4(7):499-511.
[7]	SINGH S P, WILLIAMS Y U, KLEBBA P E, et al. Immune recognition of porin and lipopolysaccharide epitopes of Salmonella Typhimurium in mice[J]. Microb Pathog, 2000, 28(3):157-167.
[8]	ALDAPA-VEGA G, MORENO-EUTIMIO M A, BERLANGA-TAYLOR A J, et al. Structural variants of Salmonella Typhimurium lipopolysaccharide induce less dimerization of TLR4/MD-2 and reduced pro-inflammatory cytokine production in human monocytes[J]. Mol Immunol, 2019, 111:43-52.
[9]	STEIMLE A, AUTENRIETH I B, FRICK J S. Structure and function:lipid A modifications in commensals and pathogens[J]. Int J Med Microbiol, 2016, 306(5):290-301.
[10]	ROSADINI C V, KAGAN J C. Early innate immune responses to bacterial LPS[J]. Curr Opin Immunol, 2017, 44:14-19.
[11]	BARKER J H, WEISS J P. Detecting lipopolysaccharide in the cytosol of mammalian cells:Lessons from MD-2/TLR4[J]. J Leukoc Biol, 2019, 106(1):127-132.
[12]	PARK B S, SONG D H, KIM H M, et al. The structural basis of lipopolysaccharide recognition by the TLR4-MD-2 complex[J]. Nature, 2009, 458(7242):1191-1195.
[13]	VANAJA S K, RUSSO A J, BEHL B, et al. Bacterial outer membrane vesicles mediate cytosolic localization of LPS and caspase-11 activation[J]. Cell, 2016, 165(5):1106-1119.
[14]	HAGAR J A, POWELL D A, AACHOUI Y, et al. Cytoplasmic LPS activates caspase-11:implications in TLR4-independent endotoxic shock[J]. Science, 2013, 341(6151):1250-1253.
[15]	KAYAGAKI N, WONG M T, STOWE I B, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4[J]. Science, 2013, 341(6151):1246-1249.
[16]	SHI J J, ZHAO Y, WANG Y P, et al. Inflammatory caspases are innate immune receptors for intracellular LPS[J]. Nature, 2014, 514(7521):187-192.
[17]	MATA-HARO V, CEKIC C, MARTIN M, et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4[J]. Science, 2007, 316(5831):1628-1632.
[18]	REED S G, CARTER D, CASPER C, et al. Correlates of GLA family adjuvants' activities[J]. Semin Immunol, 2018, 39:22-29.
[19]	HOHMANN E L, OLETTA C A, KILLEEN K P, et al. phoP/phoQ-deleted Salmonella Typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers[J]. J Infect Dis, 1996, 173(6):1408-1414.
[20]	ZHAO Y, ARCE-GORVEL V, CONDE-ÁLVAREZ R, et al. Vaccine development targeting lipopolysaccharide structure modification[J]. Microbes Infect, 2018, 20(9-10):455-460.
[21]	BERTANI B, RUIZ N. Function and biogenesis of lipopolysaccharides[J]. EcoSal Plus, 2018, 8(1):10.
[22]	LITTLEJOHN J R, DA SILVA R F, NEALE W A, et al. Structural definition of hSP-D recognition of Salmonella enterica LPS inner core oligosaccharides reveals alternative binding modes for the same LPS[J]. PLoS One, 2018, 13(6):e0199175.
[23]	MANSFIELD L P, FORSYTHE S J. Demonstration of the Rb1 lipopolysaccharide core structure in Salmonella strains with the monoclonal antibody M105[J]. J Med Microbiol, 2001, 50(4):339-344.
[24]	ERRIDGE C, BENNETT-GUERRERO E, POXTON I R. Structure and function of lipopolysaccharides[J]. Microbes Infect, 2002, 4(8):837-851.
[25]	ŠIMOLIŪNAS E, VILKAITYTĖ M, KALINIENE L, et al. Incomplete LPS core-specific Felix01-like virus vB_EcoM_VpaE1[J]. Viruses, 2015, 7(12):6163-6181.
[26]	YETHON J A, GUNN J S, ERNST R K, et al. Salmonella enterica serovar Typhimurium waaP mutants show increased susceptibility to polymyxin and loss of virulence in vivo[J]. Infect Immun, 2000, 68(8):4485-4491.
[27]	CONDE-ÁLVAREZ R, ARCE-GORVEL V, GIL-RAMÍREZ Y, et al. Lipopolysaccharide as a target for brucellosis vaccine design[J]. Microb Pathog, 2013, 58:29-34.
[28]	HARPER M, BOYCE J D, ADLER B. The key surface components of Pasteurella multocida:capsule and lipopolysaccharide[M]//AKTORIES K, ORTH J H C, ADLER B. Pasteurella multocida. Berlin:Springer, 2012:39-51.
[29]	LETAROV A V, KULIKOV E E. Adsorption of bacteriophages on bacterial cells[J]. Biochemistry (Mosc), 2017, 82(13):1632-1658.
[30]	REEVES P R, CUNNEEN M M, LIU B, et al. Genetics and evolution of the Salmonella galactose-initiated set of O antigens[J]. PLoS One, 2013, 8(7):e69306.
[31]	FIERER J, GUINEY D G. Diverse virulence traits underlying different clinical outcomes of Salmonella infection[J]. J Clin Invest, 2001, 107(7):775-780.
[32]	LIU D, VERMA N K, ROMANA L K, et al. Relationships among the rfb regions of Salmonella serovars A, B, and D[J]. J Bacteriol, 1991, 173(15):4814-4819.
[33]	LIU B, KNIREL Y A, FENG L, et al. Structural diversity in Salmonella O antigens and its genetic basis[J]. FEMS Microbiol Rev, 2014, 38(1):56-89.
[34]	KONG Q K, YANG J, LIU Q, et al. Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of Salmonella enterica serovar Typhimurium[J]. Infect Immun, 2011, 79(10):4227-4239.
[35]	JIAO Y, XIA Z M, ZHOU X H, et al. Signature-tagged mutagenesis screening revealed the role of lipopolysaccharide biosynthesis gene rfbH in smooth-to-rough transition in Salmonella Enteritidis[J]. Microbiol Res, 2018, 212-213:75-79.
[36]	KIM M, KIM S, PARK B, et al. Core lipopolysaccharide-specific phage SSU5 as an auxiliary component of a phage cocktail for Salmonella biocontrol[J]. Appl Environ Microbiol, 2014, 80(3):1026-1034.
[37]	WHITFIELD C, KANIUK N, FRIRDICH E. Molecular insights into the assembly and diversity of the outer core oligosaccharide in lipopolysaccharides from Escherichia coli and Salmonella[J]. J Endotoxin Res, 2003, 9(4):244-249.
[38]	HEINRICHS D E, YETHON J A, WHITFIELD C. Molecular basis for structural diversity in the core regions of the lipopolysaccharides of Escherichia coli and Salmonella enterica[J]. Mol Microbiol, 1998, 30(2):221-232.
[39]	PUTKER F, BOS M P, TOMMASSEN J. Transport of lipopolysaccharide to the Gram-negative bacterial cell surface[J]. FEMS Microbiol Rev, 2015, 39(6):985-1002.
[40]	BITTNER L M, ARENDS J, NARBERHAUS F. When, how and why?Regulated proteolysis by the essential FtsH protease in Escherichia coli[J]. Biol Chem, 2017, 398(5-6):625-635.
[41]	KATZ C, RON E Z. Dual role of FtsH in regulating lipopolysaccharide biosynthesis in Escherichia coli[J]. J Bacteriol, 2008, 190(21):7117-7122.
[42]	MAHALAKSHMI S, SUNAYANA M R, SAISREE L, et al. yciM is an essential gene required for regulation of lipopolysaccharide synthesis in Escherichia coli[J]. Mol Microbiol, 2014, 91(1):145-157.
[43]	EMIOLA A, ANDREWS S S, HELLER C, et al. Crosstalk between the lipopolysaccharide and phospholipid pathways during outer membrane biogenesis in Escherichia coli[J]. Proc Natl Acad Sci USA, 2016, 113(11):3108-3113.
[44]	MI W, LI Y Y, YOON S H, et al. Structural basis of MsbA-mediated lipopolysaccharide transport[J]. Nature, 2017, 549(7671):233-237.
[45]	SILHAVY T J, KAHNE D, WALKER S. The bacterial cell envelope[J]. Cold Spring Harb Perspect Biol, 2010, 2(5):a000414.
[46]	HICKS G, JIA Z C. Structural basis for the lipopolysaccharide export activity of the bacterial lipopolysaccharide transport system[J]. Int J Mol Sci, 2018, 19(9):2680.
[47]	LI Y Y, ORLANDO B J, LIAO M F. Structural basis of lipopolysaccharide extraction by the LptB2FGC complex[J]. Nature, 2019, 567(7749):486-490.
[48]	KANG X L, YANG Y, MENG C, et al. Safety and protective efficacy of Salmonella Pullorum spiC and rfaH deletion rough mutant as a live attenuated DIVA vaccine candidate[J]. Poult Sci, 2022, 101(3):101655.
[49]	SENEVIRATHNE A, HEWAWADUGE C, LEE J H. Assessing an O-antigen deficient, live attenuated Salmonella Gallinarium strain that is DIVA compatible, environmentally safe, and protects chickens against fowl typhoid[J]. Dev Comp Immunol, 2022, 133:104433.
[50]	GUO R X, JIAO Y, LI Z Y, et al. Safety, protective immunity, and DIVA capability of a rough mutant Salmonella Pullorum vaccine candidate in broilers[J]. Front Microbiol, 2017, 8:547.
[51]	KANTELE A, PAKKANEN S H, SIITONEN A, et al. Live oral typhoid vaccine Salmonella Typhi Ty21a-a surrogate vaccine against non-typhoid Salmonella?[J]. Vaccine, 2012, 30(50):7238-7245.
[52]	MACLENNAN C A. Antibodies and protection against invasive Salmonella disease[J]. Front Immunol, 2014, 5:635.
[53]	DALBY T, RASMUSSEN E, SCHIELLERUP P, et al. Development of an LPS-based ELISA for diagnosis of Yersinia enterocolitica O:3 infections in Danish patients:a follow-up study[J]. BMC Microbiol, 2017, 17(1):125.
[54]	FALKENHORST G, CEPER T H, STRID M A, et al. Serological follow-up after non-typhoid Salmonella infection in humans using a mixed lipopolysaccharide ELISA[J]. Int J Med Microbiol, 2013, 303(8):533-538.
[55]	SIMPSON B W, TRENT M S. Pushing the envelope:LPS modifications and their consequences[J]. Nat Rev Microbiol, 2019, 17(7):403-416.